Onconetix, Inc. Stock: price and insider trades · United States

Onconetix, Inc. is a Health Care company. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 24 October 2026, 6 filings were filed, from 1 insider.

The record shows 3 purchases on the open market worth €130k, made by 1 insider, against 3 sales worth €123k by 1 insider. The net balance comes to €6,845 on the buying side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. HRT Financial LP filed the largest sale, €60k, on 21 April 2026, which represents 2.4% of the company's market value. On the buying side, the filings list 1 major shareholder among the declarants.

The last purchase on record was published on 21 April 2026, which is 202 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade.

With 6 filings in twelve months, the company is quieter than the median of 24 filings across the 3,167 companies we follow on the same exchange. Over the whole record (from 2022), the tally stands at 3 purchases and 8 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 815,371 USD and net income of -14.0 m USD.

For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.